Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis
GlobalData has released its new PharmaPoint Drug Evaluation report, Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. Fostamatinib is an oral, small molecule that disrupts B-cell receptor-mediated signaling by inhibiting SYK. Its action affects the inflammatory mechanisms of TNF-a, IL-1, and IL-6. An in-license deal in 2010 has allowed the joint venture between Rigel Pharmaceuticals and AstraZeneca to bring this drug to Phase III development for oncology and RA. Regulatory filings are anticipated for 2013
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fostamatinib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fostamatinib for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fostamatinib performance
- Obtain sales forecast for Fostamatinib from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)